We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP TIDMVRP March 9, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it granted the following options over ordinary shares of GBP0.05 each (the "Ordinary Shares") and American Depositary Shares ("ADS") and restricted share units ("RSUs") and Restricted American Depositary Share Units ("RADSUs") to directors and employees of Verona Pharma under and in accordance with Verona Pharma's 2017 Incentive Award Plan (which is set out in Verona Pharma's 2017 annual report and 20-F): -- 1,798,767 options to purchase Ordinary Shares; -- 36,510 options to purchase ADSs, representing 292,080 Ordinary Shares; -- 246,570 RSUs; and -- 3,352 RADSUs, representing 26,816 Ordinary Shares. Each RSU and RADSU represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or the equivalent number of ADSs, as applicable, or an amount in cash or other consideration. Except where the context indicates otherwise, references hereunder to the Ordinary Shares shall be deemed to include a number of ADSs equal to an Ordinary Share. No consideration was paid in respect of the grant of awards. PDMR Dealings Verona Pharma notifies the following transactions by persons discharging managerial responsibilities ("PDMRs") in its Ordinary Shares through the grant of options over Ordinary Shares and ADSs and RSUs under and in accordance with Verona Pharma's 2017 Incentive Award Plan. Name Options over RSUs and RADSUs Dr. 868,758 Ordinary Shares 136,986 RSUs Jan-Anders Karlsson Piers 304,063 Ordinary Shares 47,944 RSUs Morgan Dr. Ken 10,316 ADSs 1,626 RADSUs Newman (Representing 82,528 Ordinary Shares) (Representing 13,008 RSUs) The options over Ordinary Shares have an exercise price of GBP1.46 per Ordinary Share, being the closing mid-market price on March 8, 2017. The options over ADSs have an exercise price of GBP11.68 per ADS, on the basis that each ADS represents 8 ordinary shares. The RSUs also have a value of GBP1.46 per RSU and the RADSUs have a value of GBP11.68 per RADSU. The options, RSUs and RADSUs set forth in the table above will vest as to 50% of the Ordinary Shares or ADSs (as appropriate) in three substantially equal annual instalments following the grant date and as to 50% of the Ordinary Shares or ADSs (as appropriate) in four substantially equal annual instalments following the grant date. The notification of dealing form in respect of option/RSU awards for each PDMR can be found below. For further information, please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200 Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) Stewart Wallace / Jonathan Senior / Ben Maddison Tel: +44 (0) 20 7710 7600 SNELVeronaPharma@stifel.com FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000 Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Dr. Jan-Anders Karlsson 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Verona Pharma plc b) Legal Entity Identifier 213800EVI6O6J3TIAL06 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 5p each Identification code ISIN Code: GB00BYW2KH80 b) Nature of the transaction Issue of options over Ordinary Shares c) Price(s) and volume(s) Price(s) Volume(s) Exercise Options over 868,758 Ordinary Shares Price: GBP1.46 d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction London Stock Exchange, AIM Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 5p each Identification code ISIN Code: GB00BYW2KH80 Grant of RSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or an amount in cash or other b) Nature of transaction consideration c) Price(s) and volume(s) Price(s) Volume(s) No consideration 136,986 d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction London Stock Exchange, AIM 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Piers Morgan 2 Reason for the notification a) Position/status Chief Financial Officer b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Verona Pharma plc b) Legal Entity Identifier 213800EVI6O6J3TIAL06 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 5p each Identification code ISIN Code: GB00BYW2KH80 b) Nature of the transaction Issue of options over Ordinary Shares c) Price(s) and volume(s) Price(s) Volume(s) Exercise Price: Options over 304,063 Ordinary Shares GBP1.46 d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction London Stock Exchange, AIM Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary shares of 5p each Identification code ISIN Code: GB00BYW2KH80 Grant of RSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one Ordinary Share or an amount in cash or other b) Nature of transaction consideration c) Price(s) and volume(s) Price(s) Volume(s) No consideration 47,944 d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction London Stock Exchange, AIM 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Dr. Ken Newman 2 Reason for the notification
a) Position/status Chief Medical Officer b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Verona Pharma plc b) Legal Entity Identifier 213800EVI6O6J3TIAL06 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument American Depositary Shares ("ADSs"), representing ordinary shares of 5p each, on deposit with a U.S. banking institution selected by the Company and which are registered pursuant to a Form F-6. Identification code ISIN Code: GB00BYW2KH80 b) Nature of the transaction Issue of options over ADSs c) Price(s) and volume(s) Price(s) Volume(s) Exercise Price: Options over 10,316 ADSs GBP11.68 (representing 82,528 Ordinary Shares) d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction NASDAQ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument ADSs Identification code ISIN Code: US9250501064 b) Nature of transaction Grant of RADSUs, each of which represents an unfunded, unsecured right to receive, on the applicable settlement date, one ADS or an amount in cash or other consideration c) Price(s) and volume(s) Price(s) Volume(s) No 1,626 consideration (representing 13,008 Ordinary Shares) d) Aggregated information N/a (single transaction) - Aggregated volume - Price e) Date of the transaction 8 March 2018 f) Place of the transaction NASDAQ This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Verona Pharma plc via Globenewswire http://www.veronapharma.com/
(END) Dow Jones Newswires
March 09, 2018 09:24 ET (14:24 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions